Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.34 |
| ▸ | ITGAV | P06756 | 4/20 | 0.34 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11855735 | 0.96 | KCNH2 (0.36) | KCNH2ITGAVITGB6ITGB3IRAK4 | |
| SCHEMBL3858516 | 0.90 | CTSK (0.34) | KCNH2IRAK4ACHECXCR4 | |
| SCHEMBL4073537 | 0.84 | ACHE (0.35) | IRAK4ACHECXCR4 | |
| SCHEMBL11522401 | 0.79 | KCNH2 (0.36) | KCNH2ITGAVITGB6ITGB3 | |
| SCHEMBL11475771 | 0.76 | ITGAV (0.32) | KCNH2ITGAVITGB6ITGB3 | |
| SCHEMBL11523030 | 0.75 | ITGAV (0.38) | ITGAVITGB6ITGB3EDNRBEDNRA | |
| SCHEMBL4071023 | 0.74 | CYP11B1 (0.32) | IRAK4 | |
| SCHEMBL2363782 | 0.74 | KCNH2 (0.41) | KCNH2SPHK1EDNRBEDNRA | |
| SCHEMBL11475774 | 0.74 | ITGAV (0.34) | ITGAVITGB6ITGB3ACHEEDNRB | |
| SCHEMBL2357160 | 0.73 | KCNH2 (0.49) | KCNH2ITGAVITGB6ITGB3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2350051-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056549-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT6 | KCNH2 3453/4885SPHK1 952/4885ITGAV 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.